Search
Find exactly what you’re looking for.
Search

Section
Topics
Industry
Service
Insights
Series
Podcast
Location
Media
Showing 101-120 of 218 results

This year could be the perfect storm for mergers and acquisitions in the cannabis industry, according to cannabis law attorney Zachary Kobrin. Kobrin told Green Market Report, a news outlet focused on the financial side of the cannabis industry, that he is “very bullish on M&A” for 2023 and expects...

Zachary Kobrin spoke on a panel titled, “Opportunities and Challenges in the 2023 Cannabis Market” presented by Centri Business Consulting. This webinar featured a panel of experts discussing trending financial topics in the cannabis industry including: Recent updates in Capital Markets & SAFE...

Three states legalized adult recreational marijuana use in 2022 and the use of therapeutic psychedelics is gaining acceptance as two more states this year legalized their use, some cities have decriminalized their use and more states may legalize them in the future. But while use of these drugs may...
​As the cannabis industry continues to grow and expand at a rapid pace, successful operators could become the targets of labeling class actions that have plagued the traditional food and beverage industry for decades, especially in plaintiff-friendly jurisdictions like California. Suits related to...

Cannabis Law Partner Zachary Kobrin in Fort Lauderdale shared with Law.com his 2023 cannabis law predictions, including more consolidation and perhaps more Congressional consternation in the year ahead. Kobrin was quoted: “2023 will be a year of consolidation and reduction for the cannabis industry...
​As interest in psychedelics rises, amidst the decriminalization of psychedelic substances in various jurisdictions and the regulation of the provision of psilocybin services in Oregon, institutions of higher education may find themselves wondering how to navigate the myriad questions that come...

In this exciting presentation, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current hemp and cannabinoid and regulatory landscapes, and how they might change.

In this exciting presentation, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current hemp and cannabinoid and regulatory landscapes, and how they might change.

In this exciting presentation, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current hemp and cannabinoid and regulatory landscapes, and how they might change.
For More Information
Contact us